CTEC Global X CleanTech ETF

CRMLN-Certified Point-of-Care Testing System Provides Immediate Readings During Patient Office Visits HAYWARD, Calif., Aug. 30 /PRNewswire/ -- The need for accurate testing of cholesterol and liver function in Accutane patients is underscored by a study released last week by the University of California, San Francisco, and published in the Archives of Dermatology. The study concluded that abnormalities in cholesterol and liver enzymes in Accutane patients are even more prevalent than anticipated. Of the 13,772 patients monitored, all of whom began with normal lipid levels, 44 percent developed high levels of triglycerides, 31 percent developed high cholesterol levels and 11 percent developed abnormal liver tests. These alarming statistics make a strong case for point-of-care blood testing in doctors' offices, using instrumentation certified by the Cholesterol Reference Method Laboratory Network (CRMLN), the accuracy standard set by the Centers for Disease Control. (Photo: Newscom: http://www.newscom.com/cgi-bin/prnh/20060504/NYTH042 ) Accutane patients require complex monitoring to ensure that individuals taking the drug remain healthy. The CRMLN-certified, CLIA-waived Cholestech LDX(R) System from Cholestech Corporation (NASDAQ:CTEC) enables physicians prescribing Accutane to obtain laboratory-accurate blood results in under five minutes, with a simple finger stick. The immediate in-office risk assessment provided by the LDX system lets physicians determine the appropriate therapeutic course of action for elevated total cholesterol, triglycerides and ALT-AST (Alanine Aminotransferase-Aspartate Aminotransferase) levels without delay. Additionally, the Cholestech LDX eliminates the administrative overhead costs of external lab testing, while introducing a new potential source of revenue to the practice. About the LDX System With accuracy comparable to a reference lab, results using the Cholestech LDX are achieved in five minutes or less. The health professional collects a blood sample using a simple fingerstick, inserts a cassette into the portable LDX system, and receives results within minutes. Patient counseling can begin immediately, while practice efficiency begins to accrue. "The speed and accuracy of lipid and liver enzyme results in Accutane patients is more critical than ever in view of the University of California study widely reported last week. The Cholestech LDX provides a simple and effective method to monitor the health of Accutane patients in-office, using a single instrument with a small fingerstick blood sample. And because the administrative cost in sending a patient to the lab, tracking results and scheduling follow up consultations is eliminated, Cholestech LDX helps safeguard the health of Accutane patients, while lowering practice overhead," said Warren E. Pinckert II, Cholestech President and CEO. About Cholestech Cholestech is committed to enabling people to lead longer, healthier and more active lives. Cholestech provides easy to use, accessible diagnostic tools and information to health care practitioners in over 35 countries around the world. Cholestech offers efficient and economic diagnostic testing for cholesterol and related lipids, blood glucose and glycemic control, and liver enzymes at the point of care. Health care providers can use the CLIA-waived Cholestech LDX(R) and GDX(TM) Systems and the hs-CRP test, which is cleared by the FDA for use in moderate complexity labs, to initiate and monitor the progress of patient therapy. By providing effective disease management solutions, Cholestech's goal is to be a leading provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease and diabetes. NOTE: Cholestech LDX(R) is a registered trademark and Cholestech GDX(TM) is a trademark of Cholestech Corporation. All other trademarks mentioned in this document are the property of their respective owners. For more information about Cholestech and its products visit us on the web at http://www.cholestech.com/. Contact: Julie Gross Gelfand HLD/Blankman Public Relations 516-536-6811 http://www.newscom.com/cgi-bin/prnh/20060504/NYTH042 http://photoarchive.ap.org/ DATASOURCE: Cholestech Corporation CONTACT: Julie Gross Gelfand of HLD/Blankman Public Relations, +1-516-536-6811, or , for Cholestech Web site: http://www.cholestech.com/

Copyright